Neuropeptide receptor positive allosteric modulation in epilepsy: galanin modulation revealed.
Hoyer
Daniel
D
Neuropsychiatry/Neuroscience Research, WSJ-386/745, Novartis Institutes for Biomedical Research Basel, CH 4002 Basel, Switzerland. daniel.hoyer@novartis.com
D000494:Allosteric Regulation; D000818:Animals; D004827:Epilepsy / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism*; D019004:Galanin / Q000378:metabolism* / Q000494:pharmacology*; D006801:Humans; D008024:Ligands; D008970:Molecular Weight; D044092:Receptor, Galanin, Type 2 / Q000819:agonists / Q000378:metabolism; D018013:Receptors, Neuropeptide / Q000819:agonists* / Q000378:metabolism*
D008024:Ligands; D044092:Receptor, Galanin, Type 2; D018013:Receptors, Neuropeptide; D019004:Galanin